Total votes: 1

Revenue 2009 financial year: $362,000

Cash and cash equivalents June 30th 2009 was $1,866,605

Benitec is a ribonucleic acid interference (RNAi)-based therapeutics company using its deoxyribonucleic acid (DNA)-directed RNA interference (ddRNAi) technology to develop therapies for the treatment of life threatening diseases.

The Company’s primary therapeutic program focuses on human immunodeficiency virus (HIV). Its other projects are in the area of infectious diseases and cancer.

It also licenses its technology outside of its in-house programs in order to generate revenue to support its corporate and operational activities.

Key research relationships (formal and informal) currently exist with the following groups in the areas of target
identification and delivery technology:

 - Division of Molecular Biology: City of Hope (Duarte, California USA);
 - Gene & Stem Cell Therapy Group: Centenary Institute of Cancer Medicine and Cell Biology (NSW Australia);
 - Gene Therapy Research Unit: Children’s Medical Research Institute & Westmead Children’s Hospital (NSW Australia);
 - Centre for Reproduction and Development: Monash Institute of Medical Research (Victoria Australia)
 - Biomics Biotechnology Nantong, China.

During the fiscal year ended June 30, 2009 (fiscal 2009), the principal activity of the Company was the management, funding and commercialization of these projects. It operates in a single segment, including global commercialization (by licensing and partnering) of patents and licenses developed in the area of biotechnology, specifically in functional genomics, with applications in biomedical research and human therapeutics.

Some leading players in the same field:
 - Merck see our sister USA website
 - Tekmira Pharmaceuticals
 - Silence Therapeutics